Your Health, We Care
Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved Test,who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) .Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).
FDA,2022.12
Mechanism of Action of AdagrasibSpecific alterations in the KRAS gene produce an abnormally structured KRAS protein that remains persistently activated, continuously transmitting p···【more】
Article source：Lucius LaosRelease date：2026-04-22Recommended：30
What is adagrasib?Adagrasib is an oral prescription targeted therapy designed for cancer patients with a KRAS G12C mutation. It is not a chemotherapy drug; instead, it works by pre···【more】
Article source：Lucius LaosRelease date：2026-04-21Recommended：29
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：53
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
